{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:02:11Z","timestamp":1787497331026,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Project on Chronic Disease Management of the National Health Commission","award":["GWJJMB202510022055"],"award-info":[{"award-number":["GWJJMB202510022055"]}]},{"name":"Talent Project of Beijing Municipal Committee","award":["2016000021469G211"],"award-info":[{"award-number":["2016000021469G211"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sitagliptin, a dipeptidyl peptidase-4 inhibitors (DPP-4i), was commonly used as the hypoglycaemic agent, while the impact on blood pressure (BP) in type 2 diabetes mellitus (T2DM) remained unknown. The present study aimed to evaluate the effects of sitagliptin therapy on modulating systolic BP (SBP) and diastolic BP (DBP) in T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, and the Cochrane Library was conducted for randomized controlled trials (RCTs) examining the impact of sitagliptin on SBP and DBP in T2DM. Given to the inherent clinical heterogeneity, a random-effect model was used for the overall meta-analysis. Publication bias and sensitivity analysis were conducted using standard methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 24 studies were identified. Treatment with sitagliptin was associated with a reduction in SBP (WMD\u2009=\u2009\u2212\u00a02.57\u00a0mmHg, 95% CI \u2212\u00a04.40 to \u2212\u00a00.75;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u20090%; P\u2009=\u20090.006) and DBP (WMD\u2009=\u2009\u2212\u00a01.09\u00a0mmHg, 95% CI \u2212\u00a02.16 to \u2212\u00a00.03;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u20090%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04) compared to placebo in patients with T2DM. Exploratory subgroup analysis suggested a potential trend toward BP reduction according to the subgroup analysis on treatment duration, BMI, HbA1c and dosage. The leave-one-out sensitivity analysis supported the robustness of these pooled effects. No significant publication bias was observed in BP parameters across the RCTs according to Begg\u2019s and Egger\u2019s tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of sitagliptin was associated with a reduction of BP in patients with T2DM. However, its clinical role remained primarily glycemic control. The potential reduction of BP might be considered an ancillary benefit rather than a substitute for standard antihypertensive therapy.<\/jats:p>\n                    <jats:p>International prospective register for systematic review (PROSPERO) number: CRD42026128657.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-026-04138-w","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:56:43Z","timestamp":1772254603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of sitagliptin on blood pressure in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"31","author":[{"given":"Liying","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengbao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"4138_CR1","doi-asserted-by":"publisher","DOI":"10.4137\/CMT.S6227","author":"KMS Johnson","year":"2011","unstructured":"Johnson KMS, Schurr K. Sitagliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Med Insights Ther. 2011. https:\/\/doi.org\/10.4137\/CMT.S6227.","journal-title":"Clin Med Insights Ther"},{"key":"4138_CR2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190980","author":"D-k Zeng","year":"2019","unstructured":"Zeng D-k, Xiao Q, Li F-q, Tang Y-z, Jia C-l, Tang X-w. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. 2019. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20190980."},{"key":"4138_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40256-020-00423-z","volume":"21","author":"CI Liakos","year":"2020","unstructured":"Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs. 2020;21:123\u201337.","journal-title":"Am J Cardiovasc Drugs"},{"key":"4138_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7326\/M23-1490","volume":"177","author":"T Drake","year":"2024","unstructured":"Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med. 2024;177:618\u201332.","journal-title":"Ann Intern Med"},{"key":"4138_CR5","volume":"9","author":"M Razavi","year":"2022","unstructured":"Razavi M, Wei YY, Rao XQ, Zhong JX. DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res. 2022;9:45.","journal-title":"Mil Med Res"},{"key":"4138_CR6","doi-asserted-by":"publisher","DOI":"10.4021\/jocmr1061w","author":"U Kubota","year":"2012","unstructured":"Kubota U. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012. https:\/\/doi.org\/10.4021\/jocmr1061w.","journal-title":"J Clin Med Res"},{"key":"4138_CR7","first-page":"869","volume":"12","author":"S Yongquan","year":"2017","unstructured":"Yongquan S. Effects of DPP-4 inhibitors on cardiovascular risk in type 2 diabetic patients. Chin J Endocrinol Metab. 2017;12:869.","journal-title":"Chin J Endocrinol Metab"},{"key":"4138_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1620\/tjem.223.133","volume":"223","author":"S Ogawa","year":"2011","unstructured":"Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133\u20135.","journal-title":"Tohoku J Exp Med"},{"key":"4138_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","volume":"106","author":"KM Love","year":"2021","unstructured":"Love KM, Liu Z. DPP4 activity, hyperinsulinemia, and atherosclerosis. J Clin Endocrinol Metab. 2021;106:1553\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"4138_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuaf209","author":"L Zhao","year":"2025","unstructured":"Zhao L, Meng J, Li J, Cong H, Liu C, Yang Y, et al. Dipeptidyl peptidase-4 inhibitors improved lipid levels in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Rev. 2025. https:\/\/doi.org\/10.1093\/nutrit\/nuaf209.","journal-title":"Nutr Rev"},{"key":"4138_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1210\/js.2017-00312","volume":"1","author":"JR Wilson","year":"2017","unstructured":"Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and type 2 diabetes are associated with decreased inhibition of dipeptidyl peptidase-4 by sitagliptin. J Endocr Soc. 2017;1:1168\u201378.","journal-title":"J Endocr Soc"},{"key":"4138_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","volume":"16","author":"NA Subrahmanyan","year":"2021","unstructured":"Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM. Efficacy and cardiovascular safety of DPP-4 inhibitors. Curr Drug Saf. 2021;16:154\u201364.","journal-title":"Curr Drug Saf"},{"key":"4138_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","volume":"11","author":"Y Xie","year":"2023","unstructured":"Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023;11:644\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4138_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1089\/dia.2016.0302","volume":"18","author":"X Cai","year":"2016","unstructured":"Cai X, Gao X, Yang W, Chen Y, Zhou L, Zhang S, et al. DPP-4 inhibitor treatment in Chinese type 2 diabetes patients: a meta-analysis. Diabetes Technol Ther. 2016;18:784\u201393.","journal-title":"Diabetes Technol Ther"},{"key":"4138_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s13300-017-0309-9","volume":"8","author":"T Mita","year":"2017","unstructured":"Mita T, Katakami N, Shiraiwa T, Yoshii H, Gosho M, Shimomura I, et al. Dose-dependent effect of sitagliptin on carotid atherosclerosis in patients with type 2 diabetes mellitus receiving insulin treatment: a post hoc analysis. Diabetes Ther. 2017;8:1135\u201346.","journal-title":"Diabetes Ther"},{"key":"4138_CR16","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1177\/0091270011420153","volume":"52","author":"JP Gibbs","year":"2012","unstructured":"Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, et al. Quantitative model of the relationship between Dipeptidyl Peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol. 2012;52:1494\u2013505.","journal-title":"J Clin Pharmacol"},{"key":"4138_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005892","author":"K Esposito","year":"2015","unstructured":"Esposito K, Chiodini P, Maiorino MI, Capuano A, Cozzolino D, Petrizzo M, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24\u2005163 patients. BMJ Open. 2015. https:\/\/doi.org\/10.1136\/bmjopen-2014-005892.","journal-title":"BMJ Open"},{"key":"4138_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"key":"4138_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.CCM.0000253394.15628.FD","volume":"35","author":"A Delaney","year":"2007","unstructured":"Delaney A, Bagshaw SM, Ferland A, Laupland K, Manns B, Doig C. The quality of reports of critical care meta-analyses in the Cochrane database of systematic reviews: an independent appraisal. Crit Care Med. 2007;35:589\u201394.","journal-title":"Crit Care Med"},{"key":"4138_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"4138_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023;35:414-428.e413.","journal-title":"Cell Metab"},{"key":"4138_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109171","volume":"183","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li H, Gao H, Xu X, Cai T, Wang H, et al. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes. Diabetes Res Clin Pract. 2022;183:109171.","journal-title":"Diabetes Res Clin Pract"},{"key":"4138_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5414\/CP204288","volume":"61","author":"M Athar","year":"2023","unstructured":"Athar M, Garg A, Khan MA, Parveen R, Kohli S, Vohora D. Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: an observational study. Int J Clin Pharmacol Ther. 2023;61:102\u201310.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4138_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041061","volume":"104","author":"M Qin","year":"2025","unstructured":"Qin M, Chao L, Liu S. Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: a single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis. Medicine (Baltimore). 2025;104:e41061.","journal-title":"Medicine (Baltimore)"},{"key":"4138_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"4138_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrneph.2014.18","volume":"10","author":"M Razzak","year":"2014","unstructured":"Razzak M. Transplantation: sitagliptin-balancing cardiovascular risk, hyperglycaemia and safety. Nat Rev Nephrol. 2014;10:183.","journal-title":"Nat Rev Nephrol"},{"key":"4138_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142243","author":"SI Taylor","year":"2021","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI142243.","journal-title":"J Clin Invest"},{"key":"4138_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"4138_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0372-7","volume":"15","author":"X Liu","year":"2016","unstructured":"Liu X, Men P, Wang Y, Zhai S, Liu G. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15:204.","journal-title":"Lipids Health Dis"},{"key":"4138_CR30","first-page":"892","volume":"122","author":"MYK Gul-Kahraman","year":"2021","unstructured":"Gul-Kahraman MYK, Serhatlioglu I, Onalan E, Akkopru MC, Sahna E. A new perspective on the pleiotropic blood pressure improvement effect of sitagliptin: downregulation of miRNA-155 and miRNA-21. Bratisl Lek Listy. 2021;122:892\u20139.","journal-title":"Bratisl Lek Listy"},{"key":"4138_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1086-4","volume":"18","author":"X Liu","year":"2019","unstructured":"Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18:144.","journal-title":"Lipids Health Dis"},{"key":"4138_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01955-9","volume":"29","author":"L Zhao","year":"2024","unstructured":"Zhao L, Meng J, Bai X, Zhang D, Yang X, Yang Y, et al. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus. Eur J Med Res. 2024;29:363.","journal-title":"Eur J Med Res"},{"key":"4138_CR33","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jdiacomp.2017.05.016","volume":"31","author":"SL Atkin","year":"2017","unstructured":"Atkin SL, Katsiki N, Banach M, Mikhailidis DP, Pirro M, Sahebkar A. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-\u03b1 concentrations: a systematic review and meta-analysis of controlled trials. J Diabetes Complications. 2017;31:1458\u201364.","journal-title":"J Diabetes Complications"},{"key":"4138_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/jir.2018.0144","volume":"39","author":"S Borzouei","year":"2019","unstructured":"Borzouei S, Sheikh V, Ghasemi M, Zamani A, Telikani Z, Zareighane Z, et al. Anti-inflammatory effect of combined sitagliptin and vitamin D3 on cytokines profile in patients with type 2 diabetes mellitus. J Interferon Cytokine Res. 2019;39:293\u2013301.","journal-title":"J Interferon Cytokine Res"},{"key":"4138_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-016-0144-6","author":"L Duvnjak","year":"2016","unstructured":"Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016. https:\/\/doi.org\/10.1186\/s13098-016-0144-6.","journal-title":"Diabetol Metab Syndr"},{"key":"4138_CR36","first-page":"309","volume":"4","author":"A Kubota","year":"2012","unstructured":"Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4:309\u201313.","journal-title":"J Clin Med Res"},{"key":"4138_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.curtheres.2016.12.002","volume":"84","author":"Y Tsurutani","year":"2017","unstructured":"Tsurutani Y, Omura M, Matsuzawa Y, Saito J, Higa M, Taniyama M, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin on atherosclerosis, \u03b2-cell function, and glycemic control in Japanese patients with type 2 diabetes mellitus who are treatment na\u00efve or poorly responsive to antidiabetes agents: a multicenter, prospective observational, uncontrolled study. Curr Ther Res Clin Exp. 2017;84:26\u201331.","journal-title":"Curr Ther Res Clin Exp"},{"key":"4138_CR38","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.2174\/1381612823666170519144841","volume":"23","author":"V Katsi","year":"2017","unstructured":"Katsi V, Georgiopoulos G, Vogiatzi G, Oikonomou D, Megapanou M, Skoumas J, et al. Effects of oral and non-insulin injectable antidiabetic treatment in hypertension: a systematic review. Curr Pharm Des. 2017;23:3743\u201350.","journal-title":"Curr Pharm Des"},{"key":"4138_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70087","author":"LY Lin","year":"2025","unstructured":"Lin LY, Wu JS, Jeng WJ, Tsai CH, Sun JW, Kuo CH, et al. Ocular complications of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in T2DM treatments: a retrospective real-world cohort study. Clin Pharmacol Ther. 2025. https:\/\/doi.org\/10.1002\/cpt.70087.","journal-title":"Clin Pharmacol Ther"},{"key":"4138_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/00325481.2024.2426442","volume":"136","author":"S Geng","year":"2024","unstructured":"Geng S, Li Y, Ge J, Liu Y, Li Q, Chen X, et al. Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study. Postgrad Med. 2024;136:855\u201363.","journal-title":"Postgrad Med"},{"key":"4138_CR41","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan Chronic Kidney Disease Database. Diabetes Care. 2021;44:2542\u201351.","journal-title":"Diabetes Care"},{"key":"4138_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","volume":"62","author":"N Satoh-Asahara","year":"2013","unstructured":"Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62:347\u201351.","journal-title":"Metabolism"},{"key":"4138_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","volume":"57","author":"F Arturi","year":"2017","unstructured":"Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2017;57:464\u201373.","journal-title":"Endocrine"},{"key":"4138_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-012-0013-8","volume":"3","author":"RM Bergenstal","year":"2012","unstructured":"Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther. 2012;3:13.","journal-title":"Diabetes Ther"},{"key":"4138_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3335","volume":"36","author":"S Carbone","year":"2020","unstructured":"Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, et al. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: the CANA-HF study. Diabetes Metab Res Rev. 2020;36:e3335.","journal-title":"Diabetes Metab Res Rev"},{"key":"4138_CR46","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/1440-1681.13561","volume":"48","author":"SH Elhini","year":"2021","unstructured":"Elhini SH, Hussien AK, Omran AAE, Elsayed AA, Saeed H. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clin Exp Pharmacol Physiol. 2021;48:1589\u2013602.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4138_CR47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00380-019-01526-7","volume":"35","author":"N Fujimoto","year":"2020","unstructured":"Fujimoto N, Moriwaki K, Takeuchi T, Sawai T, Sato Y, Kumagai N, et al. Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease. Heart Vessels. 2020;35:605\u201313.","journal-title":"Heart Vessels"},{"key":"4138_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dom.12908","volume":"19","author":"KM Gadde","year":"2017","unstructured":"Gadde KM, Vetter ML, Iqbal N, Hardy E, \u00d6hman P. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19:979\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"4138_CR49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40618-018-0991-0","volume":"42","author":"P Khaloo","year":"2019","unstructured":"Khaloo P, Asadi Komeleh S, Alemi H, Mansournia MA, Mohammadi A, Yadegar A, et al. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea. J Endocrinol Invest. 2019;42:851\u20137.","journal-title":"J Endocrinol Invest"},{"key":"4138_CR50","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/dom.14085","volume":"22","author":"SG Kim","year":"2020","unstructured":"Kim SG, Kim KJ, Yoon KH, Chun SW, Park KS, Choi KM, et al. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. Diabetes Obes Metab. 2020;22:1869\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"4138_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4239\/wjd.v4.i1.8","volume":"4","author":"Y Kojima","year":"2013","unstructured":"Kojima Y, Kaga H, Hayashi S, Kitazawa T, Iimura Y, Ohno M, et al. Comparison between sitagliptin and nateglinide on postprandial lipid levels: the STANDARD study. World J Diabetes. 2013;4:8\u201313.","journal-title":"World J Diabetes"},{"key":"4138_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/dia.2011.0296","volume":"14","author":"S Koren","year":"2012","unstructured":"Koren S, Shemesh-Bar L, Tirosh A, Peleg RK, Berman S, Hamad RA, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14:561\u20137.","journal-title":"Diabetes Technol Ther"},{"key":"4138_CR53","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2337\/dc17-0061","volume":"40","author":"JA Lovshin","year":"2017","unstructured":"Lovshin JA, Rajasekeran H, Lytvyn Y, Lovblom LE, Khan S, Alemu R, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1\u03b1(1-67) in patients with type 2 diabetes. Diabetes Care. 2017;40:1073\u201381.","journal-title":"Diabetes Care"},{"key":"4138_CR54","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1210\/jc.2012-1544","volume":"97","author":"A Makdissi","year":"2012","unstructured":"Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012;97:3333\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"4138_CR55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2337\/dc15-2145","volume":"39","author":"T Mita","year":"2016","unstructured":"Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39:455\u201364.","journal-title":"Diabetes Care"},{"key":"4138_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jdi.12142","volume":"5","author":"H Mori","year":"2014","unstructured":"Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:313\u20139.","journal-title":"J Diabetes Investig"},{"key":"4138_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1507\/endocrj.EJ16-0291","volume":"63","author":"A Nishimura","year":"2016","unstructured":"Nishimura A, Usui S, Kumashiro N, Uchino H, Yamato A, Yasuda D, et al. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: a randomized 24-week open-label clinical trial. Endocr J. 2016;63:1087\u201398.","journal-title":"Endocr J"},{"key":"4138_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164255","volume":"11","author":"H Nomoto","year":"2016","unstructured":"Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, et al. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS ONE. 2016;11:e0164255.","journal-title":"PLoS ONE"},{"key":"4138_CR59","first-page":"153","volume":"6","author":"T Nozue","year":"2016","unstructured":"Nozue T, Fukui K, Koyama Y, Fujii H, Kunishima T, Hikita H, et al. Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-a serial integrated backscatter-intravascular ultrasound study. Am J Cardiovasc Dis. 2016;6:153\u201362.","journal-title":"Am J Cardiovasc Dis"},{"key":"4138_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","volume":"14","author":"H Oe","year":"2015","unstructured":"Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.","journal-title":"Cardiovasc Diabetol"},{"key":"4138_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108119","volume":"162","author":"K Tanimura-Inagaki","year":"2020","unstructured":"Tanimura-Inagaki K, Nagao M, Harada T, Sugihara H, Moritani S, Sasaki J, et al. Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: a randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study. Diabetes Res Clin Pract. 2020;162:108119.","journal-title":"Diabetes Res Clin Pract"},{"key":"4138_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1530\/EJE-15-0637","volume":"174","author":"M Tian","year":"2016","unstructured":"Tian M, Liang Z, Liu R, Li K, Tan X, Luo Y, et al. Effects of sitagliptin on circulating zinc-\u03b12-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial. Eur J Endocrinol. 2016;174:147\u201355.","journal-title":"Eur J Endocrinol"},{"key":"4138_CR63","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2337\/dc16-1371","volume":"39","author":"L Tonneijck","year":"2016","unstructured":"Tonneijck L, Smits MM, Muskiet MH, Hoekstra T, Kramer MH, Danser AH, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2016;39:2042\u201350.","journal-title":"Diabetes Care"},{"key":"4138_CR64","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/dom.14023","volume":"22","author":"DR Webb","year":"2020","unstructured":"Webb DR, Htike ZZ, Swarbrick DJ, Brady EM, Gray LJ, Biglands J, et al. A randomized, open-label, active comparator trial assessing the effects of 26\u2009weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes Obes Metab. 2020;22:1187\u201396.","journal-title":"Diabetes Obes Metab"},{"key":"4138_CR65","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology. 2019;69:2414\u201326.","journal-title":"Hepatology"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04138-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:18:55Z","timestamp":1775571535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04138-w","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20190980","asserted-by":"subject"}]},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"498"}}